# Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

> **NCT01478633** · PHASE4 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 102 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Galantamine

## Key facts

- **NCT ID:** NCT01478633
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2014-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01478633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01478633, "Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01478633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*